Qing Tang gold one hundred treatment of allergic rhinitis caused by postnasal drip syndrome clinical observation_0.docVIP

 PAGE \* MERGEFORMAT 8 Qing Tang gold one hundred treatment of allergic rhinitis caused by postnasal drip syndrome clinical observation Of: Teng Lei, look over Xiang, Xin Yao Jie, Zhang Jun Jun [Abstract] Objective To observe the clear gold one hundred treating allergic rhinitis caused by postnasal drip syndrome patients. Methods 120 patients with allergic rhinitis caused by postnasal drip syndrome were randomly divided into treatment group (n = 60 ) and control group (60 cases), the former gold one hundred clear soup with fried free particles blunt, which cetirizine hydrochloride tablets orally, intranasally plus ketotifen, for 2 weeks, the clinical groups were observed after treatment effect. The results of treatment of allergic rhinitis, total effective rate was 85.00%, 91.67% in the control group; no significant difference between the two groups (Pgt; 0.05). for the treatment of postnasal drip syndrome effects The total effective rate was 88.33%, 78.33% in control group, the difference was significant (P lt;0.01). Conclusion Qing Tang gold one hundred treatment of allergic rhinitis symptoms caused by postnasal drip effect is clear that the treatment postnasal drip syndrome ideal prescription. [Keywords:] Qing Tang gold one hundred; postnasal drip syndrome; rhinitis; allergic; Perennial Postnasal drip syndrome (PNDs) as caused by many causes, brought to the difficulty of treatment. Chinese Medical Association credits will be developed respiratory disease lt;lt;cough diagnosis and treatment guidelines (Draft) ““ (2006) [1] proposed by cause of treatment for therapeutic purposes, but the clinical findings, a simple treatment for the cause can not be completely effective in improving signs and symptoms of PNDs. allergic rhinitis (AR) is a common disease caused by PNDs. I use lt;lt;Management of virtual dollars Kamgt; gt; Qing gold one hundred PNDs60 treating patients with AR caused, are summarized below. 1 Clinical data Section I General Infor